• KAFM
  • Contact us
  • E-Submission
ABOUT
ARTICLE CATEGORY
BROWSE ARTICLES
AUTHOR INFORMATION

Page Path

5
results for

"Statin"

Filter

Article category

Keywords

Publication year

"Statin"

Case Report

A Possible Case of Statin-Induced Ichthyosis in an Elderly Woman
Ki Dong Ko, Kyoung Kon Kim, Jin-Ok Baek, Heuy Sun Suh, In Cheol Hwang
Korean J Fam Med 2018;39(1):51-53.   Published online January 23, 2018
DOI: https://doi.org/10.4082/kjfm.2018.39.1.51

Ichthyosis is a heterogeneous group of hereditary or acquired skin disorders, characterized by increased stratum corneum production. Several systemic diseases and many drugs can occasionally cause acquired ichthyosis. We report a case of statin-induced ichthyosis in which the causality between statin and ichthyosis was found possible by using the Naranjo scale. A 79-year-old woman presented with pruritic skin lesions on both legs that appeared erythematous, scaly, and cracked. A clinical diagnosis of acquired ichthyosis was made and the statin was suspected as the cause. The skin lesions improved after 6 weeks of dose reduction of the statin.

Citations

Citations to this article as recorded by  
  • Mimicry in Cutaneous Malignancy—Rare Forms of Mycosis Fungoides as Diagnostic Pitfalls: A Narrative Review
    Marija Malinić, Branislav Lekić, Dubravka Živanović
    Medicina.2026; 62(4): 616.     CrossRef
  • Safety and efficacy of topical simvastatin plus cholesterol cream versus topical simvastatin cream alone for porokeratosis ptychotropica: A randomized, single-blind, split-body, placebo-controlled, investigator-initiated trial
    Zhiming Chen, Yihe Liu, Hui Yu, Jing Li, Xin Huang, Ruiyu Xiang, Ran Mo, Hao Chen, Yong Yang
    Journal of the American Academy of Dermatology.2025; 93(4): 980.     CrossRef
  • Acquired ichthyosis, asteatotic dermatitis or xerosis? An update on pathoetiology and drug‐induced associations
    Jason S. Park, Amir H. Saeidian, Leila Youssefian, Sylvia Hsu, Hassan Vahidnezhad, Jouni Uitto
    Journal of the European Academy of Dermatology and Venereology.2023; 37(1): 47.     CrossRef
  • Acquired ichthyosis: a clinical review
    Roger Haber, Joelle Feghali, Umer Nadir, Michael D. Yi, Brian A. Cahn
    Archives of Dermatological Research.2023; 315(9): 2529.     CrossRef
  • Ichthyosis (concept, pathohistology, clinical picture, treatment)
    Tatyana Gennadyevna Takhtarova, Zarema Rimovna Khismatullina, Lyudmila Dmitrievna Panova, Anastasia Nikolaevna Panova
    Vestnik dermatologii i venerologii.2021; 97(3): 6.     CrossRef
  • 7,458 View
  • 79 Download
  • 5 Web of Science
  • 5 Crossref

Original Article

Factors of Compliance in Patients with Hypercholesterolemia Using Rosuvastatin in Primary Care
Hye Young Kim, Jung Ah Lee, Young Sik Kim, Sung Sunwoo, Han Jin Oh, Chang Sup Kim, Keunsang Yum, Changjin Choi, Yoo Seock Jeong, Sang-Wook Song, Dae Hyun Kim, Young Sung Kim
Korean J Fam Med 2012;33(5):253-261.   Published online September 27, 2012
DOI: https://doi.org/10.4082/kjfm.2012.33.5.253
Background

In order to evaluate the factors of compliance with a lipid lowering therapy, a prospective observational study of patients with hypercholesterolemia using rosuvastatin was carried out.

Methods

A total of 2,607 patients who were newly prescribed rosuvastatin were enrolled from 32 family physicians in Korea from March 2009 to December 2009. Of them, 301 patients were excluded due to incomplete data or follow-up compliance data. The patients were regularly observed to ascertain the compliance associated with rosuvastatin at intervals of 12 and 24 weeks. We collected risk factors for the compliance using a structured questionnaire. The criteria for evaluating compliance are to measure clinic attendance, to assess the continuity of therapy, and to calculate the percentage of doses taken.

Results

Among a total of 2,306 patients, the degree of compliance was 54.1%. According to logistic regression analysis, the factors for compliance with the lipid lowering drug included old age (odds ratio [OR], 2.68; 95% confidence interval [CI], 2.09 to 3.45), frequent exercise (OR, 1.76; 95% CI, 1.43 to 2.18), previous statin therapy (OR, 4.02; 95% CI, 3.22 to 5.01), hypertension (OR, 1.80; 95% CI, 1.48 to 2.19), diabetes mellitus (OR, 2.20; 95% CI, 1.69 to 2.87), concomitant medication (OR, 2.28; 95% CI, 1.88 to 2.77), and high coronary heart disease (CHD) risk category (OR, 1.82; 95% CI, 1.39 to 2.38). The compliance decreased with high low density lipoprotein cholesterol levels (OR, 0.20; 95% CI, 0.16 to 0.26).

Conclusion

The compliance of patients using rosuvastatin was 54.1% in primary care. The factors related to higher compliance were old age, regular exercise, previous statin therapy, concomitant medication, presence of hypertension or diabetes, and higher CHD risk level.

Citations

Citations to this article as recorded by  
  • Factors Related to Suboptimal Adherence to Dyslipidemia Medication: An Exploration Using Nationally Representative Databases
    Jihye Shin, Taegyu Um, Sangyong Jo, Minkook Son
    Journal of Lipid and Atherosclerosis.2025; 14(3): 312.     CrossRef
  • Patient-related characteristics associated with non-persistence with statin therapy in elderly patients following an ischemic stroke
    Martin Wawruch, Dusan Zatko, Gejza Wimmer, Jan Luha, Vasil Hricak, Jan Murin, Peter Kukumberg, Tomas Tesar, Adam Hloska, Rashmi Shah
    Pharmacoepidemiology and Drug Safety.2017; 26(2): 201.     CrossRef
  • Improving Medication Adherence in Coronary Heart Disease
    Leah L. Zullig, Katherine Ramos, Hayden B. Bosworth
    Current Cardiology Reports.2017;[Epub]     CrossRef
  • Risk of cardiovascular disease? A qualitative study of risk interpretation among patients with high cholesterol
    Pia Kirkegaard, Adrian Edwards, Mette Bech Risør, Janus Laust Thomsen
    BMC Family Practice.2013;[Epub]     CrossRef
  • Association Between Statin Adherence and Cholesterol Level Reduction from Baseline in a Veteran Population
    Rashid Kazerooni, Jonathan H. Watanabe, Mark Bounthavong
    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2013; 33(10): 1044.     CrossRef
  • Achieving recommended low density lipoprotein cholesterol goals and the factors associated with target achievement of hypercholesterolemia patients with rosuvastatin in primary care
    Jung Ah Lee, Sung Sunwoo, Young Sik Kim, Han Jin Oh, Hee-Cheol Kang, Kyung-Chae Park, Dong Hyuk Sin, Sang Yeoup Lee, Yun Jun Yang, Byung Yeon Yu, Chul-Min Kim
    Current Medical Research and Opinion.2013; 29(7): 751.     CrossRef
  • 5,936 View
  • 26 Download
  • 6 Crossref

Review

The Comparison of Guidelines for Management of Dyslipidemia and the Appropriateness of Them in Korea.
Young Gyu Cho, Hong Ji Song, Byung Ju Park
Korean J Fam Med 2010;31(3):171-181.   Published online March 20, 2010
DOI: https://doi.org/10.4082/kjfm.2010.31.3.171
There have been accumulating evidences that dyslipidemia is a major risk factor of cardiovascular disease (CVD) and improvement in lipid profile can reduce the incidence of CVD. Guidelines for management of dyslipidemia have been developed by major organizations in several contries including the United States. In Korea, a guideline was also published by the Korean Society of Lipidology and Atherosclerosis. However, This guideline was not based on evidences in Korea, but was made by a consensus of experts using a pre-developed guideline as a reference. For clinical application for Korean of guidelines developed in different nations, the disease epidemiology and medical environment in Korea should be considered. In this article, we reviewed whether guidelines for management of dyslipidemia are applicable in Korean context.

Citations

Citations to this article as recorded by  
  • A Possible Case of Statin-Induced Ichthyosis in an Elderly Woman
    Ki Dong Ko, Kyoung Kon Kim, Jin-Ok Baek, Heuy Sun Suh, In Cheol Hwang
    Korean Journal of Family Medicine.2018; 39(1): 51.     CrossRef
  • Relationship between health behaviors and high level of low density lipoprotein-cholesterol applying cardiovascular risk factors among Korean adults: based on the sixth Korea National Health and Nutrition Examination Survey (KNHANES VI), 2013 ~ 2015
    Bo-Kyoung Cha
    Journal of Nutrition and Health.2018; 51(6): 556.     CrossRef
  • Management Status of Cardiovascular Disease Risk Factors for Dyslipidemia among Korean Adults
    Jongseok Lee, Heejeong Son, Ohk-Hyun Ryu
    Yonsei Medical Journal.2017; 58(2): 326.     CrossRef
  • The Effect of Omega-3 Fatty Acid Supplementation on Cerebral Blood Flow and Vascular Resistance: A Preliminary Study
    Jae-Hyeok Heo, Hye-Yeon Won, Dong-Gyu Im, Jung-Hee Kim, Hee-Tae Kim, Jin-Young Ahn
    Korean Journal of Clinical Neurophysiology.2015; 17(2): 68.     CrossRef
  • Prevalence and Management of Dyslipidemia Among Korean Adults: KNHANES 2010-2012
    Sungok Jang, Jongseok Lee
    Journal of the Korea Academia-Industrial cooperation Society.2015; 16(11): 7978.     CrossRef
  • 3,605 View
  • 47 Download
  • 5 Crossref
Original Articles
The Effect of Atorvastatin on Serum Lipid Levels among Patients with Hypercholesterolemia.
Sang Sung John, Jae Hyung Park, Hyun Joo Chung, Jung Cheon Son, Kwang Min Kim, Bom Taeck Kim
J Korean Acad Fam Med 2004;25(1):46-51.   Published online January 10, 2004
Background
: Recently, the incidence of cardiovascular diseases has increased in Korea. Hypercho-lesterolemia is a major risk factor for cardiovascular diseases. Atorvastatin (Lipitor±) is prescribed for the treatment of hyperlipidemia in Korea, but its effect has not been studied. Therefore, we investigated the lipid lowering effect of atorvastatin in Koreans.

Methods : This study included 82 hypercholesterolemic patients who visited the Department of Family Practice of Ajou University Hospital from January 1, 2000 to December 31, 2001. The mean age of the subjects was 47.8 years in the range of 27 to 66 years. Our study included 41 controls and 41 subjects who were administered atorvastatin 20 mg daily for 3 months. Fasting serum lipid levels were measured at baseline and at 3 months. Specific dietary and exercise interventions were not instructed.

Results : At 3 months, the serum total cholesterol and LDL were significantly lower in atorvastatin group than in the control group (Total cholesterol; -5.5±16.7%, vs 25.5±15.8%, P<0.05, LDL cholesterol; 1.4±28.5%, vs -30.1±28.9%, P<0.05). The serum triglyceride in atorvastain group showed no significant difference relative to the controls (Control: -5.8±34.2%, Atorvastatin: -3.5±54.8%, P=0.81). But, Serum triglyceride level decreased by -14.3±33.2% in the control and -39.0±23.2% in the atorvastatin group among the patients whose baseline triglyceride level was over 200 mg/dl (P<0.05). There was no significant differences in HDL-cholesterol (Control: 3.0±22.6%, Atorvastatin: -0.9±18.8%, P=0.38). The effect of atorvastatin was not influenced by age, sex, BMI and other risk factors.

Conclusion : Atorvastatin lowered significantly the serum total cholesterol, LDL and triglycerides in Korea. Regardless of age, sex, BMI, but had no effect on HDL level.
  • 2,051 View
  • 29 Download
The effects on serum lipoprotein(a) of antihyperlipidemic agents.
Ki Tae Kim, Sung Je Park, Young Sung Suh, Dae Hyun Kim, Dong Hak Shin
J Korean Acad Fam Med 2000;21(2):234-243.   Published online February 1, 2000
Background
: Many studies to reduce serum lipoprotein(a) are done because serum lipoprotein(a) has been known to be an independent risk factor of coronary artery disease along with age, smoking, diabetes, hypertension, and hyperlipidemia. Till now, oral estrogen/androgen therapy, niacin analogue and plasmapheresis are known therapeutic methods. This study examined the relative effects of three antihyperlipidemic agents, acipimox, lovastatin, fenofibrate.

Methods : Among 70 subjects(male-19, female-51) with their serum cholesterol level of more than 240mg/dL, 56 subjects who were completed 2 months antihyperlipidemic treatment (acipimox-20, lovastatin-18, fenofibrate-18) were examined for baseline total cholesterol, HDL cholesterol, triglyceride, and lipoprotein(a) and were followed up 2 months later.

Results : Mean values of each group for acipimox, lovastatin, fenofibrate were as follows: total cholesterol (268.1±19.03, 287.1±36.42, 268.9±25.99), HDL cholesterol (43.5±10.99, 42.7±11.88, 37.9±8.20), triglyceride (226.1±165.03, 260.4±175.98, 234.3±124.33), LDL cholesterol (179.3±30.40, 192.3±41.52, 184.1±38.08), lipoprotein(a) (26.2±15.32,34.8±18.56,29.9±12.58). Mean percentile reduction of lipoprotein(a) was acipimox-41.4%(P<0.0001), lovastatin-22.2%(P<0.0001), fenofibrate-16.1%(P<0.05), and p value was less than 0.05 in the comparison of groups. Lipoprotein (a) showed no relations with age, sex, BMI, WHR, smoking, total cholesterol, HDL cholesterol, triglyceride and LDL cholesterol. After 2 months treatment, mean reduction percentages of total cholesterol was acipimox-12.2%(P<0.0001), lovastatin-17.6%(P<0.0001), fenofibrate-8.85%(P<0.05). LDL cholesterol was acipimox-16.12%(P<0.0001), lovastatin-22.89%(P<0.0001), fenofibrate-12.06% (P<0.05). Triglyceride was acipimox-17.24%(P<0.0001), lovastatin-17.39%(p<0.0001), fenofibrate-9.78%(p<0.05). HDL cholesterol was elevated in acipimox-17.24%(P<0.05), lovastatin-16.10%(P<0.05) and fenofibrate-12.06(P<0.05). In total cholesterol(P<0.05) and LDL cholesterol(P<0.05), there were significant differences among 3 groups, but not in HDL cholesterol and triglycerides.

Conclusion : In two months treatment of acipimox, lovastatin and fenofibrate in hyperlipidemic patients, lipoprotein(a), known for independent risk factor of coronary artery disease, was reduced significantly in the order of acipimox, lovastatin and fenofibrate.
  • 1,720 View
  • 13 Download
TOP